Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025
-
Rail journey offers a slower route to a Berlin city break
-
Energy bill plan could use HMRC income data to target support
-
Arsenal control title race as Manchester United fall into bottom three
-
Business owner earning £6,000 a month tackles £70,000 debt
-
Suspected Krakow gunman dies after attack that killed six
-
Nvidia chief faces inquiry after disclosing affair with suspected Chinese agent
-
Carrick backs Dalot after hostile reception from Manchester United fans
-
Comet returns as online electrical marketplace 14 years after collapse
-
Aston Villa Defy History With Rare Victory at Old Trafford
-
Brussels Education Unions Schedule Major November Protest Over Funding and Reforms
-
Crowds Gather at San Francisco Park for Elizabeth Holmes Lookalike Tournament
-
Hancock Health Expands Robot Specimen Delivery to Parkway Building, Adding Scheduled and On-Demand Runs to the Lab
-
Releaf Unveils UK-first THCV for Weight Management
-
Gabriel Provides Corporate Update
-
AsiaFIN's Insite MY Holdings and MENA Insite MY Sign Distributorship Agreement and Announce Second Bank Customer in Saudi Arabia
-
Ai4 Celebrates Successful Debut of Applied AI Research Conference (AAIRC), Bridging Academic Research and Industry Innovation
-
Medicus Pharma to Highlight Rationale for CD228V Co-Development and License Agreement
-
Nextech3D.ai Closes $720,000 Management-Led Private Placement
-
CoTec Holdings Corp. Notes HyProMag USA Advances North Texas Rare Earth Magnet Facility With First Major Equipment Delivery
-
Silver Storm Reports Concentrate Deliveries from La Parrilla
-
Ispire Technology Inc. Reports First Quarter Fiscal Year 2027 Financial Results
-
HyProMag USA Advances North Texas Rare Earth Magnet Facility With First Major Equipment Delivery
-
Hillcrest and Equipmake Sign Definitive Agreement to Jointly Develop and License ZVS Inverter Technology for Heavy-Duty Electric Vehicles
-
Tintina Mines Intersects 460m at 0.50% CuEq at the Dos Amigos Copper-Gold Project in Chile
-
Pace Launches Three-Business-Day Culture-Based 'L. pneumophila' Testing
-
Opti Digital Launches NEXA, an AI-Powered Intelligence Layer
-
DataMEDS AI Announces Corexa Pharmacy's First Commercial Sale of Compounded Peptides Under FDA Enforcement Discretion Policy
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 09
-
Making Your Home Safer for Aging Parents: Accessibility Renovations That Add Value
-
New 401k Gold IRA Investment Guide Explains the Best Way to Invest in Gold for Retirement (2026 Update)
-
United States Antimony Corporation Announces Webcast Time set for Thursday, November 12, 2026 at 4:15 PM ET to Report on Third Quarter and Nine Months Ended September 30, 2026 Financial and Operating Results
-
Pacific Edge Labs Publishes More Than 120 Independent Lab Reports, Each Listed With the Testing Lab's Own ID
-
Regentis Signs Exclusive Distribution Agreement with AMI Technologies to Commercialize GelrinC(R) in Israel
-
Modular Medical Completes Comprehensive Patient Market Research Study with Thrivable, Reinforcing Strong Interest in Simplified Insulin Delivery
-
Shelfietech Launched New Retail Software Platform
-
A Holiday-Season Moment for Penny-Stock Followers and Microcap Visionaries as Elektros Moves Its EV Patent Forward
-
Dolphin Subsidiary 42West Drives Global Communications Behind Box Office Leaders Godzilla Minus Zero and Ramayana
-
Visterra Landscape Group Expands Into Arkansas With Strategic Investment In Little Rock Landscape
-
Santa Claus Has Come Early: Elektros Brings An Early-Christmas Spark To Its Patented EV Charging Vision
-
SMX Is Building a Verifiable Identity Layer for Fashion, From Cotton Fields to Luxury Resale
-
Gladstone Land Corporation Earnings Call and Webcast Information
-
The Metals Royalty Company to Host Corporate Update Webinar on November 16, 2026
-
Aptevo Presents Preclinical Data at SITC 2026 Showing Potential to Overcome Immune Suppression in Solid Tumors
-
Eylsia Nicolas Launches Global "Wake Me Up" Franchise After Surpassing 100 Million Meta Views in One Week
-
BioLargo Targets Growing Industrial PFAS Market with MasterClass at International Water Conference
-
Jericho Energy Ventures to Participate in Cantor Convergence 4th Annual Crypto and AI Infrastructure Conference
-
IGC Pharma Reports Third Quarter 2026 Financial Results and Provides Business Update
-
Tectonic Metals Adds Mine Development and Alaska Native Partnership Leaders Ahead of 2027 Mineral Resource Estimate and Preliminary Economic Assessment
-
iPS Cell Research Accelerates Drug Discovery for ALS and Spinal Cord Injury
-
Central Tokyo Apartment Rents Forecast to Rise 11% by 2030
Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025
DENVER, CO / ACCESS Newswire / November 5, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its first quarter of fiscal 2026, after the market close on Thursday, November 13, 2025. The Company has scheduled a conference call and webcast that same day, Thursday, November 13, 2025, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.
Conference Call Details
Date and Time: Thursday, November 13, 2025, at 4:30 p.m. Eastern time.
Call-in Information: Interested parties can access the conference call by dialing (888) 506-0062 for United States callers or +1 (973) 528-0011 for international callers and using the participant access code 240426.
Webcast Information: The webcast will be accessible live and archived at https://www.webcaster5.com/Webcast/Page/2142/53111, and accessible on the Investors section of the Company's website at https://investors.aytubio.com/ under Events & Presentations.
Replay: A teleconference replay of the call will be available until November 27, 2025, at (877) 481-4010 for United States callers or +1 (919) 882-2331 for international callers and using replay access code 53111.
About Aytu BioPharma
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD) and treatments for attention deficit-hyperactivity disorder (ADHD). Aytu is committed to delivering our medications through best-in-class patient access programs that help to enable optimal patient outcomes. For more information, please visit aytubio.com or follow us on LinkedIn.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
[email protected]
Robert Blum
Lytham Partners
[email protected]
SOURCE: Aytu BioPharma, Inc.
View the original press release on ACCESS Newswire
P.Martin--AMWN